• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

含有具有检测干扰潜力的化合物的靶标-配体复合物的 X 射线结构。

X-ray Structures of Target-Ligand Complexes Containing Compounds with Assay Interference Potential.

机构信息

Department of Life Science Informatics, B-IT, LIMES Program Unit Chemical Biology and Medicinal Chemistry, Rheinische Friedrich-Wilhelms-Universität , Dahlmannstr. 2, D-53113 Bonn, Germany.

Pharmaceutical Institute, Rheinische Friedrich-Wilhelms-Universität , An der Immenburg 4, D-53121 Bonn, Germany.

出版信息

J Med Chem. 2018 Feb 8;61(3):1276-1284. doi: 10.1021/acs.jmedchem.7b01780. Epub 2018 Jan 24.

DOI:10.1021/acs.jmedchem.7b01780
PMID:29328660
Abstract

Pan assay interference compounds (PAINS) have become a paradigm for compound classes that might cause artifacts in biological assays. PAINS-defining substructures are typically contained in larger compounds. We have systematically examined X-ray structures of protein-ligand complexes for compounds containing PAINS motifs. In 2874 X-ray structures, 1107 unique ligands with PAINS substructures belonging to 70 different classes were identified. PAINS most frequently detected in crystallographic ligands included a number of prominent candidates such as quinones, catechols, or Mannich bases. However, on the basis of X-ray data, the presence of specific ligand-target interactions and reactivity under assay conditions were not mutually exclusive. In some instances, reactivity of ligands was likely responsible for complex formation. Different categories of PAINS-containing ligands were distinguished, which aided in the interpretation of specific interactions versus potential assay artifacts. Careful consideration of structural data adds another dimension to the analysis of interference compounds.

摘要

泛分析干扰化合物 (PAINS) 已经成为一类可能在生物分析中产生假象的化合物的范例。PAINS 定义的亚结构通常包含在较大的化合物中。我们系统地检查了含有 PAINS 基序的化合物的蛋白质-配体复合物的 X 射线结构。在 2874 个 X 射线结构中,鉴定出 70 个不同类别中含有 PAINS 亚结构的 1107 个独特配体。在晶体学配体中最常检测到的 PAINS 包括一些著名的候选物,如醌、儿茶酚或曼尼希碱。然而,根据 X 射线数据,特定配体-靶标相互作用的存在和在测定条件下的反应性并非相互排斥。在某些情况下,配体的反应性可能是复合物形成的原因。区分了不同类别的含有 PAINS 的配体,这有助于解释特定的相互作用与潜在的测定假象。对结构数据的仔细考虑为干扰化合物的分析增加了另一个维度。

相似文献

1
X-ray Structures of Target-Ligand Complexes Containing Compounds with Assay Interference Potential.含有具有检测干扰潜力的化合物的靶标-配体复合物的 X 射线结构。
J Med Chem. 2018 Feb 8;61(3):1276-1284. doi: 10.1021/acs.jmedchem.7b01780. Epub 2018 Jan 24.
2
Exploring Activity Profiles of PAINS and Their Structural Context in Target-Ligand Complexes.探索 PAINS 的活性特征及其在靶标-配体复合物中的结构背景。
J Chem Inf Model. 2018 Sep 24;58(9):1847-1857. doi: 10.1021/acs.jcim.8b00385. Epub 2018 Aug 27.
3
Machine Learning Distinguishes with High Accuracy between Pan-Assay Interference Compounds That Are Promiscuous or Represent Dark Chemical Matter.机器学习能够高精度地区分具有混杂性或代表暗物质的泛分析干扰化合物。
J Med Chem. 2018 Nov 21;61(22):10255-10264. doi: 10.1021/acs.jmedchem.8b01404. Epub 2018 Nov 13.
4
Toward an Understanding of Pan-Assay Interference Compounds and Promiscuity: A Structural Perspective on Binding Modes.从结构角度理解全分析干扰化合物和混杂性:结合模式。
J Chem Inf Model. 2021 May 24;61(5):2248-2262. doi: 10.1021/acs.jcim.0c01227. Epub 2021 Apr 26.
5
How Frequently Are Pan-Assay Interference Compounds Active? Large-Scale Analysis of Screening Data Reveals Diverse Activity Profiles, Low Global Hit Frequency, and Many Consistently Inactive Compounds.泛分析干扰化合物的出现频率有多高?大规模筛选数据的分析揭示了多样化的活性特征、低的全球命中频率以及许多始终不活跃的化合物。
J Med Chem. 2017 May 11;60(9):3879-3886. doi: 10.1021/acs.jmedchem.7b00154. Epub 2017 Apr 25.
6
How to Triage PAINS-Full Research.如何对PAINS-Full研究进行分诊。
Assay Drug Dev Technol. 2016 Apr;14(3):168-74. doi: 10.1089/adt.2015.674. Epub 2015 Oct 23.
7
Phantom PAINS: Problems with the Utility of Alerts for Pan-Assay INterference CompoundS.幻痛:泛分析干扰化合物警报的效用问题
J Chem Inf Model. 2017 Mar 27;57(3):417-427. doi: 10.1021/acs.jcim.6b00465. Epub 2017 Feb 25.
8
Atom-centered interacting fragments and similarity search applications.基于原子中心的相互作用片段及其相似性搜索应用。
J Chem Inf Model. 2010 Jan;50(1):79-86. doi: 10.1021/ci9004223.
9
X-ray crystallography in drug discovery.药物研发中的X射线晶体学
Methods Mol Biol. 2009;572:31-56. doi: 10.1007/978-1-60761-244-5_3.
10
Feeling Nature's PAINS: Natural Products, Natural Product Drugs, and Pan Assay Interference Compounds (PAINS).感受大自然的“痛点”:天然产物、天然产物药物与泛分析干扰化合物(PAINS)
J Nat Prod. 2016 Mar 25;79(3):616-28. doi: 10.1021/acs.jnatprod.5b00947. Epub 2016 Feb 22.

引用本文的文献

1
A new ChEMBL dataset for the similarity-based target fishing engine FastTargetPred: Annotation of an exhaustive list of linear tetrapeptides.用于基于相似性的靶点筛选引擎FastTargetPred的新ChEMBL数据集:线性四肽详尽列表的注释
Data Brief. 2022 Apr 11;42:108159. doi: 10.1016/j.dib.2022.108159. eCollection 2022 Jun.
2
Gains from no real PAINS: Where 'Fair Trial Strategy' stands in the development of multi-target ligands.无实际痛苦的收获:“公平试验策略”在多靶点配体开发中的地位。
Acta Pharm Sin B. 2021 Nov;11(11):3417-3432. doi: 10.1016/j.apsb.2021.02.023. Epub 2021 Mar 4.
3
Identification of novel scaffolds targeting Mycobacterium tuberculosis.
鉴定新型针对结核分枝杆菌的支架。
J Mol Med (Berl). 2019 Nov;97(11):1601-1613. doi: 10.1007/s00109-019-01840-7. Epub 2019 Nov 14.
4
Promiscuous Ligands from Experimentally Determined Structures, Binding Conformations, and Protein Family-Dependent Interaction Hotspots.来自实验确定结构、结合构象和蛋白质家族依赖性相互作用热点的混杂配体。
ACS Omega. 2019 Jan 22;4(1):1729-1737. doi: 10.1021/acsomega.8b03481. eCollection 2019 Jan 31.
5
Targeting the Small GTPase Superfamily through Their Regulatory Proteins.靶向小 GTP 酶超家族及其调节蛋白。
Angew Chem Int Ed Engl. 2020 Apr 16;59(16):6342-6366. doi: 10.1002/anie.201900585. Epub 2020 Jan 30.
6
An Indole-Chalcone Inhibits Multidrug-Resistant Cancer Cell Growth by Targeting Microtubules.一种吲哚查尔酮通过靶向微管抑制多药耐药癌细胞生长。
Mol Pharm. 2018 Sep 4;15(9):3892-3900. doi: 10.1021/acs.molpharmaceut.8b00359. Epub 2018 Aug 9.